Drug intelligence / Profile preview

enoxacin

Development stage
Phase 2
Lead developer
Sanofi
Modality
Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Enoxacin is a broad-spectrum, orally active fluoroquinolone antibiotic used primarily for the treatment of urinary tract infections and gonorrhea. It acts as a bactericidal agent by inhibiting bacterial DNA gyrase (DNA topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination in bacteria. This inhibition prevents the untwisting of DNA required for replication and cell division. Enoxacin is effective against both Gram-positive and Gram-negative bacteria, including some strains resistant to other antibiotics with different mechanisms of action. The drug is rapidly absorbed after oral administration with high bioavailability and achieves high concentrations in the urinary tract[1][2][3][4][5][6][7]. Developed as part of the quinolone class, it has also been studied for its effects on microRNA processing via TRBP-dependent pathways[8].

Brand names
Penetrex
Other names
enoxacinum
02

Targets

Topo IV (Bacterial Topoisomerase IV)DNA gyrase

Beyond the preview

Go deeper on enoxacin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on enoxacin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call